Smaller drugmakers beat Big Pharma in partnering popularity contest

Big Pharma companies aren't the most popular partners for biotechs looking to out-license products, a Boston Consulting survey found. Even top-scoring GlaxoSmithKline ($GSK) has moved down in the ranks, as smaller drugmakers like Celgene ($CELG) and Novo Nordisk ($NVO) moved up to first and second place. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.